
USFDA APPLICATION NUMBER - 203826 / DOSAGE - SOLUTION;INTRAVENOUS - 10MG/ML (10MG/ML)
| Active Ingredient/Active Moiety | ||
| Ingredient Name | Basis of Strength | Strength | 
|---|---|---|
| PHENYLEPHRINE HYDROCHLORIDE(UNII: 04JA59TNSJ) (PHENYLEPHRINE - UNII:1WS297W6MV)  | PHENYLEPHRINE HYDROCHLORIDE | 10mg in 1 | 
Inactive Ingredients
| Ingredient Name | Avadel Legacy Pharmaceuticals, LLC  | Accord Healthcare, Inc.  | BluePoint Laboratories  | Cardinal Health  | Cipla USA Inc.  | General Injectables & Vaccines, Inc  | General Injectables and Vaccines, Inc.  | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.  | Hikma Pharmaceuticals USA Inc.  | Ingenus Pharmaceuticals, LLC  | Medical Purchasing Solutions, LLC  | REMEDYREPACK INC.  | 
					
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE (2968PHW8QP) | ||||||||||||
| CITRIC ACID MONOHYDRATE(2968PHW8QP) | ||||||||||||
| EDETATE DISODIUM(7FLD91C86K) | ||||||||||||
| HYDROCHLORIC ACID(QTT17582CB) | ||||||||||||
| SODIUM CHLORIDE(451W47IQ8X) | ||||||||||||
| SODIUM CITRATE(1Q73Q2JULR) | ||||||||||||
| SODIUM HYDROXIDE(55X04QC32I) | ||||||||||||
| SODIUM METABISULFITE (4VON5FNS3C) | ||||||||||||
| SODIUM METABISULFITE(4VON5FNS3C) | ||||||||||||
| TRISODIUM CITRATE DIHYDRATE(B22547B95K) | ||||||||||||
| WATER(059QF0KO0R) |